Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures

Epilepsy and Behavior

Volumn 57, Issue , 2016, Pages 95-104

  Töllner, Kathrin ^a,b   Twele, Friederike ^a,b   Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Animal models; Antiepileptic drugs; Drug resistance; Epilepsy; Levetiracetam; Phenobarbital; Valproate

Indexed keywords

DIAZEPAM; ETIRACETAM; LAMOTRIGINE; PENTETRAZOLE; PHENOBARBITAL; VALPROIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; PILOCARPINE; PIRACETAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; EPILEPTIC STATE; FEMALE; MOUSE; MOUSE MODEL; NONHUMAN; PENTYLENETETRAZOLE-INDUCED SEIZURE; SEIZURE THRESHOLD; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG RESISTANCE; EPILEPSY; EVALUATION STUDY; MALE; RAT; SEIZURES; STATUS EPILEPTICUS;

ANIMALS; ANTICONVULSANTS; DIAZEPAM; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; EPILEPSY; GABA ANTAGONISTS; MALE; MICE; PENTYLENETETRAZOLE; PHENOBARBITAL; PILOCARPINE; PIRACETAM; RATS; SEIZURES; STATUS EPILEPTICUS; VALPROIC ACID;

EID: 84959320154     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2016.01.032     Document Type: Article

References (54)

1. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011, 20:359-368.
2. Wilcox K.S., Dixon-Salazar T., Sills G.J., Ben Menachem E., White H.S., Porter R.J., et al. Issues related to development of new antiseizure treatments. Epilepsia 2013, 54(Suppl. 4):24-34.
3. Reddy D.S., Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Int J Mol Sci 2013, 14:18284-18318.
4. Gorter J.A., van Vliet E.A., Lopes Da Silva F.H. Which insights have we gained from the kindling and post-status epilepticus models?. J Neurosci Methods 2015, 260:96-108.
5. Levesque M., Avoli M., Bernard C. Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration. J Neurosci Methods 2015, 260:45-52.
6. Blanco M.M., Dos S.J., Perez-Mendes P., Kohek S.R., Cavarsan C.F., Hummel M., et al. Assessment of seizure susceptibility in pilocarpine epileptic and nonepileptic Wistar rats and of seizure reinduction with pentylenetetrazole and electroshock models. Epilepsia 2009, 50:824-831.
7. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazol seizure models. Epilepsy Res 1991, 8:171-189.
8. Löscher W., Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993, 232:147-158.
9. Bankstahl M., Bankstahl J.P., Löscher W. Pilocarpine-induced epilepsy in mice alters seizure thresholds and the efficacy of antiepileptic drugs in the 6-Hertz psychomotor seizure model. Epilepsy Res 2013, 107:205-216.
10. Löscher W., Hoffmann K., Twele F., Potschka H., Töllner K. The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. Pharmacol Res 2013, 77:39-46.
11. Gröticke I., Hoffmann K., Löscher W. Behavioral alterations in the pilocarpine model of temporal lobe epilepsy in mice. Exp Neurol 2007, 207:329-349.
12. Bankstahl M., Müller C.J., Wilk E., Schughart K., Löscher W. Generation and characterization of pilocarpine-sensitive C57BL/6 mice as a model of temporal lobe epilepsy. Behav Brain Res 2012, 230:182-191.
13. Töllner K., Brandt C., Töpfer M., Brunhofer G., Erker T., Gabriel M., et al. A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. Ann Neurol 2014, 75:550-562.
14. Finn D.A., Gee K.W. The estrus cycle, sensitivity to convulsants and the anticonvulsant effect of a neuroactive steroid. J Pharmacol Exp Ther 1994, 271:164-170.
15. Rattka M., Brandt C., Löscher W. Do proconvulsants modify or halt epileptogenesis? Pentylenetetrazole is ineffective in two rat models of temporal lobe epilepsy. Eur J Neurosci 2012, 36:2505-2520.
16. Löscher W. Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol 2009, 610:1-11.
17. Green A.R., Murray T.K. A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms. J Pharm Pharmacol 1989, 41:879-880.
18. Miller A.A., Wheatley P., Sawyer D.A., Baxter M.G., Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 1986, 27:483-489.
19. Löscher W., Fiedler M. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VI. Seasonal influences on maximal electroshock and pentylenetetrazol seizure thresholds. Epilepsy Res 1996, 25:3-10.
20. Stafstrom C.E. Epilepsy comorbidities: how can animal models help?. Adv Exp Med Biol 2014, 813:273-281.
21. Löscher W., Hönack D., Nolting B., Faβbender C.P. Trans-2-en-valproate: reevaluation of its anticonvulsant efficacy in standardized seizure models in mice, rats and dogs. Epilepsy Res 1991, 9:195-210.
22. Löscher W., Klitgaard H., Twyman R.E., Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov 2013, 12:757-776.
23. Czuczwar S.J., Turski L., Turski W., Kleinrok Z. Effects of some antiepileptic drugs in pentetrazol-induced convulsions in mice lesioned with kainic acid. Epilepsia 1981, 22:407-414.
24. Czuczwar S.J., Turski L., Kleinrok Z. Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid. Epilepsia 1982, 23:377-382.
25. Löscher W., Luna-Tortos C., Römermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des 2011, 17:2808-2828.
26. Ghosh C., Gonzalez-Martinez J., Hossain M., Cucullo L., Fazio V., Janigro D., et al. Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow. Epilepsia 2010, 51:1408-1417.
27. Leite J.P., Cavalheiro E.A. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 1995, 20:93-104.
28. Stables J.P., Bertram E., Dudek F.E., Holmes G., Mathern G., Pitkänen A., et al. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia 2003, 44:1472-1478.
29. Bankstahl M., Bankstahl J.P., Löscher W. Inter-individual variation in the anticonvulsant effect of phenobarbital in the pilocarpine rat model of temporal lobe epilepsy. Exp Neurol 2012, 234:70-84.
30. Glien M., Brandt C., Potschka H., Löscher W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002, 43:350-357.
31. Schmidt D., Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
32. Huang X., Zhang H., Yang J., Wu J., McMahon J., Lin Y., et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 2010, 40:193-199.
33. Buckmaster P.S., Lew F.H. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci 2011, 31:2337-2347.
34. Dalby N.O., Nielsen E.B. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 1997, 28:63-72.
35. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001, 47:217-228.
36. Sills G.J., Butler E., Thompson G.G., Brodie M.J. Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure 2004, 13:287-295.
37. Mandhane S.N., Aavula K., Rajamannar T. Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice. Seizure 2007, 16:636-644.
38. Getova D.P., Mihaylova A.S. A study of the effects of lamotrigine on mice using two convulsive tests. Folia Med (Plovdiv) 2011, 53:57-62.
39. Watanabe M., Miyai A., Danjo S., Nakamura Y., Itoh K. The threshold of pentylenetetrazole-induced convulsive seizures, but not that of nonconvulsive seizures, is controlled by the nitric oxide levels in murine brains. Exp Neurol 2013, 247:645-652.
40. Leclercq K., Kaminski R.M. Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. Epilepsy Behav 2015, 49:55-60.
41. Rattka M., Brandt C., Bankstahl M., Bröer S., Löscher W. Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats. Neuropharmacology 2011, 60:505-512.
42. Bröer S., Pilawski I., Löscher W., Bernard C. Opposing changes in neuronal excitability following an epileptogenic brain insult in mice and rats. Naunyn-Schmiedeberg's Arch Pharmacol 2014, 387(Suppl.1):S32.
43. Löscher W., Fiedler M. The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VII. Seasonal influences on anticonvulsant drug actions in mouse models of generalized seizures. Epilepsy Res 2000, 38:231-248.
44. Scheving L.E., Mayersbach Hv, Pauly J.E. An overview of chronopharmacology. J Eur Toxicol 1974, 7:203-227.
45. Mayersbach Hv Time - a key in experimental and practical medicine. Arch Toxicol 1976, 36:185-216.
46. Mayersbach Hv Seasonal influences on biological rhythms of standardized laboratory animals. Chronobiologia 1981, 8:87-99.
47. Gwinner E. Circannual rhythms 1986, Springer, Berlin.
48. Bartsch H., Bartsch C., Mecke D., Lippert T.H. Seasonality of pineal melatonin production in the rat - possible synchronization by the geomagnetic field. Chronobiol Int 1994, 11:21-26.
49. Károly N., Mihaly A., Dobo E. Comparative immunohistochemistry of synaptic markers in the rodent hippocampus in pilocarpine epilepsy. Acta Histochem 2011, 113:656-662.
50. Volk H.A., Burkhardt K., Potschka H., Chen J., Becker A., Löscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004, 123:751-759.
51. Bankstahl J.P., Löscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res 2008, 82:70-85.
52. Kuteykin-Teplyakov K., Brandt C., Hoffmann K., Löscher W. Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia 2009, 50:887-897.
53. Bankstahl J.P., Bankstahl M., Kuntner C., Stanek J., Wanek T., Meier M., et al. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci 2011, 31:8803-8811.
54. Baltes S., Fedrowitz M., Luna-Tortós C., Potschka H., Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 2007, 320:331-343.